JPWO2020112937A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020112937A5 JPWO2020112937A5 JP2021530887A JP2021530887A JPWO2020112937A5 JP WO2020112937 A5 JPWO2020112937 A5 JP WO2020112937A5 JP 2021530887 A JP2021530887 A JP 2021530887A JP 2021530887 A JP2021530887 A JP 2021530887A JP WO2020112937 A5 JPWO2020112937 A5 JP WO2020112937A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- sulfur
- oxygen
- compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 93
- 150000001875 compounds Chemical class 0.000 claims description 69
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 62
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 62
- 229910052760 oxygen Inorganic materials 0.000 claims description 62
- 239000001301 oxygen Chemical group 0.000 claims description 62
- 239000011593 sulfur Chemical group 0.000 claims description 62
- 229910052717 sulfur Chemical group 0.000 claims description 62
- 125000005842 heteroatom Chemical group 0.000 claims description 60
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 43
- 229920006395 saturated elastomer Polymers 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 208000035475 disorder Diseases 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 125000002950 monocyclic group Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000017701 Endocrine disease Diseases 0.000 claims description 6
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims description 6
- 208000030172 endocrine system disease Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010066946 Craniofacial dysostosis Diseases 0.000 claims description 2
- 201000006526 Crouzon syndrome Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Chemical group 0.000 claims description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 239000010703 silicon Chemical group 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024120957A JP2024160253A (ja) | 2018-11-30 | 2024-07-26 | Ｔｙｋ２阻害剤およびその使用 |
| JP2025283785A JP2026053668A (ja) | 2018-11-30 | 2025-12-26 | Ｔｙｋ２阻害剤およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773620P | 2018-11-30 | 2018-11-30 | |
| US62/773,620 | 2018-11-30 | ||
| PCT/US2019/063510 WO2020112937A1 (en) | 2018-11-30 | 2019-11-27 | Tyk2 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120957A Division JP2024160253A (ja) | 2018-11-30 | 2024-07-26 | Ｔｙｋ２阻害剤およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022509260A JP2022509260A (ja) | 2022-01-20 |
| JPWO2020112937A5 true JPWO2020112937A5 (https=) | 2022-12-05 |
| JP2022509260A5 JP2022509260A5 (https=) | 2022-12-05 |
| JP7530360B2 JP7530360B2 (ja) | 2024-08-07 |
Family
ID=70848642
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530887A Active JP7530360B2 (ja) | 2018-11-30 | 2019-11-27 | Ｔｙｋ２阻害剤およびその使用 |
| JP2024120957A Pending JP2024160253A (ja) | 2018-11-30 | 2024-07-26 | Ｔｙｋ２阻害剤およびその使用 |
| JP2025283785A Pending JP2026053668A (ja) | 2018-11-30 | 2025-12-26 | Ｔｙｋ２阻害剤およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120957A Pending JP2024160253A (ja) | 2018-11-30 | 2024-07-26 | Ｔｙｋ２阻害剤およびその使用 |
| JP2025283785A Pending JP2026053668A (ja) | 2018-11-30 | 2025-12-26 | Ｔｙｋ２阻害剤およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11053241B2 (https=) |
| EP (1) | EP3886843A4 (https=) |
| JP (3) | JP7530360B2 (https=) |
| CN (1) | CN113271938A (https=) |
| AU (1) | AU2019389025B2 (https=) |
| CA (1) | CA3120866A1 (https=) |
| IL (1) | IL283409B1 (https=) |
| WO (1) | WO2020112937A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| JP7530360B2 (ja) | 2018-11-30 | 2024-08-07 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| EP4269404A4 (en) * | 2020-12-25 | 2024-12-04 | Xizang Haisco Pharmaceutical Co., Ltd. | KETOHEXOKINASE INHIBITORS AND USE THEREOF |
| EP4308556A4 (en) | 2021-03-16 | 2025-02-19 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| TW202425965A (zh) * | 2022-09-30 | 2024-07-01 | 日商科研製藥股份有限公司 | 縮環化合物及含有其之醫藥 |
| CN115974751A (zh) * | 2022-12-13 | 2023-04-18 | 山东能源集团新材料有限公司 | 一种吡拉西坦制备方法及系统 |
| AU2023410062A1 (en) * | 2022-12-22 | 2025-08-07 | Protekt Therapeutics Ltd. | Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors |
| WO2025010294A2 (en) * | 2023-07-03 | 2025-01-09 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and use as tyk2 inhibitors |
| US11891394B1 (en) | 2023-09-06 | 2024-02-06 | King Faisal University | Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors |
| US11858935B1 (en) | 2023-09-06 | 2024-01-02 | King Faisal University | Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors |
| US11878978B1 (en) | 2023-09-06 | 2024-01-23 | King Faisal University | Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors |
| CN117342955A (zh) * | 2023-10-08 | 2024-01-05 | 盐城师范学院 | 一种制备4’-甲基-联苯-2-胺的方法 |
| WO2025222103A1 (en) * | 2024-04-19 | 2025-10-23 | Raythera, Inc. | Stat6 modulators and methods of uses thereof |
| WO2025264818A1 (en) * | 2024-06-20 | 2025-12-26 | Raythera, Inc. | Stat6 modulators and methods of uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| ID24300A (id) | 1997-08-05 | 2000-07-13 | Pfizer Prod Inc | 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| CA2569887A1 (en) * | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| ATE527258T1 (de) | 2004-07-28 | 2011-10-15 | Takeda Pharmaceutical | Pyrroloä2,3-cüpyridinverbindung, verfahren zu deren herstellung und anwendung |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| MY194668A (en) | 2012-11-08 | 2022-12-12 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses |
| US9315494B2 (en) | 2012-11-08 | 2016-04-19 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| WO2015131080A1 (en) | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| JP6484253B2 (ja) | 2014-05-01 | 2019-03-13 | ノバルティス アーゲー | Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物 |
| JP7125385B2 (ja) | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| EP3848370B1 (en) * | 2016-10-14 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| US11370794B2 (en) * | 2016-11-11 | 2022-06-28 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| JP7530360B2 (ja) | 2018-11-30 | 2024-08-07 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
-
2019
- 2019-11-27 JP JP2021530887A patent/JP7530360B2/ja active Active
- 2019-11-27 US US16/697,371 patent/US11053241B2/en active Active
- 2019-11-27 CA CA3120866A patent/CA3120866A1/en active Pending
- 2019-11-27 EP EP19888308.4A patent/EP3886843A4/en active Pending
- 2019-11-27 CN CN201980087661.3A patent/CN113271938A/zh active Pending
- 2019-11-27 WO PCT/US2019/063510 patent/WO2020112937A1/en not_active Ceased
- 2019-11-27 AU AU2019389025A patent/AU2019389025B2/en active Active
-
2021
- 2021-05-14 US US17/320,394 patent/US11834449B2/en active Active
- 2021-05-24 IL IL283409A patent/IL283409B1/en unknown
-
2024
- 2024-07-26 JP JP2024120957A patent/JP2024160253A/ja active Pending
-
2025
- 2025-12-26 JP JP2025283785A patent/JP2026053668A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020112937A5 (https=) | ||
| JP2017506675A5 (https=) | ||
| JP2018532706A5 (https=) | ||
| IL271999B1 (en) | TYK2 inhibitors and their uses | |
| JP2021518441A5 (https=) | ||
| JP2020007311A5 (https=) | ||
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JPWO2019183367A5 (https=) | ||
| WO2018013597A4 (en) | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors | |
| IL295603A (en) | Protein compounds and their uses | |
| JP2009513571A5 (https=) | ||
| JP2018507238A5 (https=) | ||
| JP2013530236A5 (https=) | ||
| JP2010510215A5 (https=) | ||
| JP2016505012A5 (https=) | ||
| JPWO2020081508A5 (https=) | ||
| JP2020511438A5 (https=) | ||
| IL274229B1 (en) | Antibacterial compounds | |
| JP2010526098A5 (https=) | ||
| JP2013515786A5 (https=) | ||
| JPWO2022174031A5 (https=) | ||
| JP2021501756A5 (https=) | ||
| JP2020506895A5 (https=) | ||
| RU2006134019A (ru) | Производные изотиомочевины |